Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial.

Bernadette de RauglaudreCamille Sibertin-BlancAurélie FabreKarine Le MalicotJaafar BennounaFrançois GhiringhelliJulien TaïebValérie BoigeOlivier BouchéThierry ChatellierRoger FarouxEric FrançoisStéphane JacquotDominique GenetClaire MulotSylviane OlschwangJean-François SeitzThomas AparicioLaetitia Dahan

Published in: Therapeutic advances in medical oncology (2022)

rs9582036 CC genotype experienced longer TCD. The presence of this genotype may thus predict a benefit of bevacizumab maintenance in mCRC.

Keyphrases

metastatic colorectal cancer
phase iii
vascular endothelial growth factor
open label
clinical trial
phase ii
double blind
placebo controlled
endothelial cells
study protocol
randomized controlled trial